Type II Diabetes Clinical Trial
— RANKL-GLYCOfficial title:
Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes
Verified date | February 2023 |
Source | Centre Hospitalier Sud Francilien |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The rapid normalization of hyperglycemia can cause a neuropathy called Diabetes Treatment-Induced Neuropathy (NITD). This phenomenon induces the presence of hyper vascularization and inflammation in contact with the nerve ends. In another register in patients living with diabetes, it has been observed the development of a rare and devastating complication for the joints called the so-called neuroarthropathy of Charcot (CN).
Status | Completed |
Enrollment | 60 |
Est. completion date | October 11, 2022 |
Est. primary completion date | October 11, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: Group G1: - Male or female patient aged 18 to 70, not practicing regular physical activity (Baecke score <10) - Patient with type 2 diabetes for at least 1 year - Patient treated with metformin +/- SU +/- DPP4 inhibitor +/- GLP1 analogue +/- insulin therapy - Patient insufficiently balanced under his current treatment with an HbA1c level> 8.5% for 6 months. - Patient able to practice physical activity on a regular basis - Patient having performed a coronary artery disease screening test in the year prior to inclusion - Woman of childbearing age with effective contraception put in place and monitored throughout the trial - Patient having given his consent to participate in the study and having signed an informed consent - Within the G1 group, a controlled 1: 1 randomization, stratified on age (=65 years or> 65 years) and BMI (= 30 or> 30) will determine the inclusion of patients in the G1A group (correction of HbA1c) or G1B (correction of HbA1c + physical activity). Group G2: - Male or female patient aged 18 to 70, not practicing regular physical activity - Patient with type 2 diabetes for at least 1 year - Patient treated with metformin +/- SU +/- DPP4 inhibitor +/- GLP1 analogue +/- insulin therapy - Patient balanced under his current treatment with an HbA1c level <7% for 6 months. - Women of childbearing potential with effective contraception put in place and monitored throughout the trial - Patient having given his consent to participate in the study and having signed an informed consent - Matching with the last patient included in group G1 on age (± 5 years), sex, duration of diabetes (± 2 years) and BMI (± 2kg / m2). Exclusion Criteria: - Fetal and maternal pathologies requiring maturation Patient with type 1 diabetes - Patient with regular physical activity - History of severe cardiovascular pathologies (myocardial infarction, or acute coronary syndrome, or stroke in the past year) - Patient with a history of severe hypoglycemia in the 6 months preceding entry into the study and / or not experiencing hypoglycemia at all - Patient pregnant or likely to be - Severe obesity (BMI> 35kg / m2) - Other pathologies likely to interfere with the glycemic variation: in particular the use of corticosteroids during the study - Patient already having Charcot's neuroarthropathy or symptomatic autonomic neuropathy: orthostatic hypotension and / or gastro-paresis - Patient with preproliferative diabetic retinopathy - Patient having anti RANKL treatment - Subject under tutorship or curatorship - Subject not affiliated to social security. |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Sud Francilien | Corbeil-Essonnes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Sud Francilien |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | RANKL/OPG level | RANKL/OPG level | at 3 months | |
Secondary | Sudoscan measurement | The Sudoscan non-invasively measures the ability of sweat glands to release chloride ions in response to an electrochemical stimulus on the palms of the hands and soles of the feet, areas with the highest density of sweat glands using four independent electrodes placed on the palms of the hands, soles of the feet which have a high density of sweat glands, | at 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT04569214 -
The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients
|
Phase 2 | |
Completed |
NCT01698528 -
Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration
|
N/A | |
Completed |
NCT00985114 -
Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
|
N/A | |
Active, not recruiting |
NCT05120219 -
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05108350 -
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02586129 -
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
|
Phase 3 | |
Completed |
NCT02914743 -
Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes
|
N/A | |
Completed |
NCT04540016 -
Mass Balance and Biotransformation of [14C]HSK7653 in Human
|
Phase 1 | |
Completed |
NCT02429258 -
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
|
Phase 4 | |
Completed |
NCT01055223 -
Fracture Risk With Thiazolidinediones
|
N/A | |
Terminated |
NCT02365233 -
Fatty Liver Study in Patients With Type II Diabetes
|
Phase 4 | |
Completed |
NCT05878587 -
Burger Allen Exercises in Knee OA With Type II Diabetes
|
N/A | |
Completed |
NCT04768673 -
A Study to Investigate the PK and Safety of CKD-393
|
Phase 1 | |
Not yet recruiting |
NCT05028140 -
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
|
Phase 3 | |
Terminated |
NCT01804777 -
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
|
Early Phase 1 | |
Completed |
NCT01619332 -
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06387433 -
Effectiveness of an mHealth Mobile App
|
N/A | |
Completed |
NCT01881074 -
Periodontal Treatment Response in Type II Diabetic Patients
|
||
Not yet recruiting |
NCT01591525 -
Diabetes Mellitus Community Based Screening in Minority Populations
|
N/A |